ONCOS 102
Alternative Names: Ad5/3-D24-GMCSF; AdV5/3-D24-GM-CSF; CGTG-102; ONCOS-102Latest Information Update: 28 Jun 2024
At a glance
- Originator Oncos Therapeutics
- Developer AstraZeneca; Ludwig Institute for Cancer Research; Oncos Therapeutics; SOTIO; Targovax
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Granulocyte-macrophage colony-stimulating factor expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Malignant-mesothelioma
- Phase I/II Colorectal cancer; Ovarian cancer
- No development reported Malignant melanoma
- Discontinued Prostate cancer; Soft tissue sarcoma; Solid tumours
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Norway (Intratumoural, Injection)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (Intratumoural, Injection)
- 22 Jun 2023 Agenus and Targovax withdraws a phase II trial prior to enrolment in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Metastatic, Treatment-resistant, Monotherapy, Second-line therapy or greater) (Intratumoral, Injection) due to strategic reason (NCT05561491)